
Florian Holsboer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3660219/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of weariness of life, suicide ideations and suicide attempt on HPA axis regulation in depression. Psychoneuroendocrinology, 2021, 131, 105286.	2.7	11
2	Evidence for an enhanced procoagulant state in remitted major depression. World Journal of Biological Psychiatry, 2020, 21, 766-774.	2.6	4
3	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	12.6	450
4	Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients. Translational Psychiatry, 2020, 10, 210.	4.8	7
5	Acute Stress-Induced Coagulation Activation in Patients With Remitted Major Depression Versus Healthy Controls and the Role of Stress-Specific Coping. Annals of Behavioral Medicine, 2020, 54, 611-618.	2.9	3
6	Polymorphisms in the BDNF and BDNFOS genes are associated with hypothalamus-pituitary axis regulation in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109686.	4.8	29
7	FKBP5 Gene Expression Predicts Antidepressant Treatment Outcome in Depression. International Journal of Molecular Sciences, 2019, 20, 485.	4.1	40
8	SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nature Communications, 2019, 10, 5770.	12.8	286
9	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192
10	Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men. JCI Insight, 2019, 4, .	5.0	5
11	Polymorphism in Tmem132d regulates expression and anxiety-related behavior through binding of RNA polymerase II complex. Translational Psychiatry, 2018, 8, 1.	4.8	263
12	Early life stress determines the effects of glucocorticoids and stress on hippocampal function: Electrophysiological and behavioral evidence respectively. Neuropharmacology, 2018, 133, 307-318.	4.1	41
13	Childhood abuse and depression in adulthood: The mediating role of allostatic load. Psychoneuroendocrinology, 2018, 94, 134-142.	2.7	56
14	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	12.8	250
15	Heart rate variability and cordance in rapid eye movement sleep as biomarkers of depression and treatment response. Journal of Psychiatric Research, 2017, 92, 64-73.	3.1	21
16	New insights into the intracellular distribution pattern of cationic amphiphilic drugs. Scientific Reports, 2017, 7, 44277.	3.3	21
17	Heterozygosity for the Mood Disorder-Associated Variant Gln460Arg Alters P2X7 Receptor Function and Sleep Quality. Journal of Neuroscience, 2017, 37, 11688-11700.	3.6	44
18	Genetically dissecting P2rx7 expression within the central nervous system using conditional humanized mice. Purinergic Signalling, 2017, 13, 153-170.	2.2	71

#	Article	IF	CITATIONS
19	Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity. PLoS Biology, 2017, 15, e2002690.	5.6	28
20	Azidobupramine, an Antidepressant-Derived Bifunctional Neurotransmitter Transporter Ligand Allowing Covalent Labeling and Attachment of Fluorophores. PLoS ONE, 2016, 11, e0148608.	2.5	5
21	Co-Expression of Wild-Type P2X7R with Gln460Arg Variant Alters Receptor Function. PLoS ONE, 2016, 11, e0151862.	2.5	21
22	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
23	Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. Journal of Psychiatric Research, 2016, 73, 86-95.	3.1	52
24	Holocaust Exposure Induced Intergenerational Effects on FKBP5 Methylation. Biological Psychiatry, 2016, 80, 372-380.	1.3	532
25	Intranasally Applied Neuropeptide S Shifts a High-Anxiety Electrophysiological Endophenotype in the Ventral Hippocampus towards a "Normal"-Anxiety One. PLoS ONE, 2015, 10, e0120272.	2.5	20
26	A genetic risk score combining 32 SNPs is associated with body mass index and improves obesity prediction in people with major depressive disorder. BMC Medicine, 2015, 13, 86.	5.5	56
27	Searching for non-genetic molecular and imaging PTSD risk and resilience markers: Systematic review of literature and design of the German Armed Forces PTSD biomarker study. Psychoneuroendocrinology, 2015, 51, 444-458.	2.7	29
28	Cell type-specific modifications of corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1) on startle behavior and sensorimotor gating. Psychoneuroendocrinology, 2015, 53, 16-28.	2.7	12
29	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
30	Pharmacological Inhibition of the Psychiatric Risk Factor FKBP51 Has Anxiolytic Properties. Journal of Neuroscience, 2015, 35, 9007-9016.	3.6	90
31	Identification and characterization of HPA-axis reactivity endophenotypes in a cohort of female PTSD patients. Psychoneuroendocrinology, 2015, 55, 102-115.	2.7	74
32	IGF-I in major depression and antidepressant treatment response. European Neuropsychopharmacology, 2015, 25, 864-872.	0.7	53
33	Cordance derived from REM sleep EEG as a biomarker for treatment response in depression – a naturalistic study after antidepressant medication. Journal of Psychiatric Research, 2015, 63, 97-104.	3.1	16
34	FKBP5 Genotype-Dependent DNA Methylation and mRNA Regulation After Psychosocial Stress in Remitted Depression and Healthy Controls. International Journal of Neuropsychopharmacology, 2015, 18, pyu087-pyu087.	2.1	60
35	A role for synapsin in FKBP51 modulation of stress responsiveness: Convergent evidence from animal and human studies. Psychoneuroendocrinology, 2015, 52, 43-58.	2.7	26
36	Neural correlates of insight in dreaming and psychosis. Sleep Medicine Reviews, 2015, 20, 92-99.	8.5	58

#	Article	IF	CITATIONS
37	Association of FKBP51 with Priming of Autophagy Pathways and Mediation of Antidepressant Treatment Response: Evidence in Cells, Mice, and Humans. PLoS Medicine, 2014, 11, e1001755.	8.4	141
38	Evidence supporting the match/mismatch hypothesis of psychiatric disorders. European Neuropsychopharmacology, 2014, 24, 907-918.	0.7	125
39	Blood Mononuclear Cell Proteome Suggests Integrin and Ras Signaling as Critical Pathways for Antidepressant Treatment Response. Biological Psychiatry, 2014, 76, e15-e17.	1.3	22
40	Increased HPA axis response to psychosocial stress in remitted depression: the influence of coping style. Biological Psychology, 2014, 103, 267-275.	2.2	35
41	Mice selected for extremes in stress reactivity reveal key endophenotypes of major depression: A translational approach. Psychoneuroendocrinology, 2014, 49, 229-243.	2.7	24
42	Are there meaningful biomarkers of treatment response for depression?. Drug Discovery Today, 2014, 19, 539-561.	6.4	58
43	Dexamethasone stimulated gene expression in peripheral blood indicates glucocorticoid-receptor hypersensitivity in job-related exhaustion. Psychoneuroendocrinology, 2014, 44, 35-46.	2.7	27
44	Hypothalamo-pituitary-adrenal axis activity evolves differentially in untreated versus treated multiple sclerosis. Psychoneuroendocrinology, 2014, 45, 87-95.	2.7	24
45	Redesigning antidepressant drug discovery. Dialogues in Clinical Neuroscience, 2014, 16, 5-7.	3.7	2
46	Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 2012, 44, 552-561.	21.4	594
47	Epigenetic Aspects of Posttraumatic Stress Disorder. Disease Markers, 2011, 30, 77-87.	1.3	46
48	Genetic Markers for PTSD Risk and Resilience Among Survivors of the World Trade Center Attacks. Disease Markers, 2011, 30, 101-110.	1.3	117
49	Stress Hormone Regulation: Biological Role and Translation into Therapy. Annual Review of Psychology, 2010, 61, 81-109.	17.7	377
50	A Genomewide Association Study Points to Multiple Loci That Predict Antidepressant Drug Treatment Outcome in Depression. Archives of General Psychiatry, 2009, 66, 966.	12.3	284
51	Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action. Psychoneuroendocrinology, 2009, 34, 238-248.	2.7	36
52	How can we realize the promise of personalized antidepressant medicines?. Nature Reviews Neuroscience, 2008, 9, 638-646.	10.2	158
53	Central CRH system in depression and anxiety — Evidence from clinical studies with CRH1 receptor antagonists. European Journal of Pharmacology, 2008, 583, 350-357.	3.5	333
54	The involvement of neuropeptides in evolution, signaling, behavioral regulation and psychopathology: focus on vasopressin. Drug Development Research, 2005, 65, 185-190.	2.9	8

#	Article	IF	CITATIONS
55	Unipolar versus bipolar disorder: A distinction not helpful for studies of causality. Current Psychiatry Reports, 2005, 7, 405-407.	4.5	3
56	High-Quality Antidepressant Discovery by Understanding Stress Hormone Physiology. Annals of the New York Academy of Sciences, 2003, 1007, 394-404.	3.8	21
57	Corticotropin-releasing hormone modulators and depression. Current Opinion in Investigational Drugs, 2003, 4, 46-50.	2.3	65
58	Antidepressant Drug Discovery in the Postgenomic Era. World Journal of Biological Psychiatry, 2001, 2, 165-177.	2.6	31
59	The anxiolytic effect of the CRH1receptor antagonist R121919 depends on innate emotionality in rats. European Journal of Neuroscience, 2001, 13, 373-380.	2.6	145
60	Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. European Journal of Neuroscience, 2001, 14, 1603-1612.	2.6	224
61	Cross-fostering and cross-breeding of HAB and LAB rats: a genetic rat model of anxiety. Behavior Genetics, 2001, 31, 371-382.	2.1	71
62	Combined Treatment with Corticosteroids and Moclobemide Favors Normalization of Hypothalamo-Pituitary-Adrenal Axis Dysregulation in Relapsing-Remitting Multiple Sclerosis: A Randomized, Double Blind Trial. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1610-1615.	3.6	13
63	Ageing alters intrahypothalamic release patterns of vasopressin and oxytocin in rats. European Journal of Neuroscience, 2000, 12, 1487-1494.	2.6	75
64	Glucocorticoid receptor impairment enhances impulsive responding in transgenic mice performing on a simultaneous visual discrimination task. European Journal of Neuroscience, 2000, 12, 2559-2569.	2.6	17
65	Acute transcranial magnetic stimulation of frontal brain regions selectively modulates the release of vasopressin, biogenic amines and amino acids in the rat brain. European Journal of Neuroscience, 2000, 12, 3713-3720.	2.6	146
66	Glucocorticoid receptor impairment alters CNS responses to a psychological stressor: an in vivo microdialysis study in transgenic mice. European Journal of Neuroscience, 2000, 12, 283-291.	2.6	89
67	Differential induction of NF-κB activity and neural cell death by antidepressantsin vitro. European Journal of Neuroscience, 2000, 12, 4331-4337.	2.6	59
68	The Corticosteroid Receptor Hypothesis of Depression. Neuropsychopharmacology, 2000, 23, 477-501.	5.4	1,859
69	The stress hormone system is back on the map. Current Psychiatry Reports, 2000, 2, 454-456.	4.5	41
70	Dose-dependent effects of endotoxin on human sleep. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 278, R947-R955.	1.8	173
71	Pharmacological Characterisation of Cortical γ-Aminobutyric Acid Type A (GABA _A) Receptors in Two Wistar Rat Lines Selectively Bred for High and Low Anxiety-Related Behaviour. World Journal of Biological Psychiatry, 2000, 1, 137-143.	2.6	12
72	Impaired glucocorticoid receptor function evolves in aberrant physiological responses to bacterial endotoxin. European Journal of Neuroscience, 1999, 11, 178-186.	2.6	20

#	Article	IF	CITATIONS
73	Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats. European Journal of Neuroscience, 1999, 11, 997-1002.	2.6	80
74	Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nature Genetics, 1998, 19, 162-166.	21.4	881
75	Hormonal Response Pattern in the Combined DEX-CRH Test Is Stable over Time in Subjects at High Familial Risk for Affective Disorders. Neuropsychopharmacology, 1998, 18, 253-262.	5.4	188
76	Effects of Clozapine on In Vitro Immune Parameters A Longitudinal Study in Clozapine-Treated Schizophrenic Patients. Neuropsychopharmacology, 1998, 19, 114-122.	5.4	59
77	Behavioral, Physiological, and Neuroendocrine Stress Responses and Differential Sensitivity to Diazepam in Two Wistar Rat Lines Selectively Bred for High- and Low-Anxiety–Related Behavior. Neuropsychopharmacology, 1998, 19, 381-396.	5.4	148
78	Sleep Endocrine Effects of Megestrol Acetate in Healthy Men. Journal of Neuroendocrinology, 1998, 10, 719-727.	2.6	7
79	Sleep-endocrine effects of mifepristone and megestrol acetate in healthy men. American Journal of Physiology - Endocrinology and Metabolism, 1998, 274, E139-E145.	3.5	20
80	Neuropeptides and Human Sleep. Sleep, 1997, , .	1.1	32
81	Infusions of Tyrosine Hydroxylase Antisense Oligodeoxynucleotide into Substantia Nigra of the Rat: Effects on Tyrosine Hydroxylase mRNA and Protein Content, Striatal Dopamine Release and Behaviour. European Journal of Neuroscience, 1997, 9, 210-220.	2.6	8
82	Protection Against Oxidative Stress-induced Neuronal Cell Death-A Novel Role for RU486. European Journal of Neuroscience, 1997, 9, 912-920.	2.6	89
83	Sleep in Schizophrenia: A Polysomnographic Study on Drug-Naive Patients. Neuropsychopharmacology, 1997, 16, 51-60.	5.4	93
84	Somatostatin Impairs Sleep in Elderly Human Subjects. Neuropsychopharmacology, 1997, 16, 339-345.	5.4	63
85	Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology, 1997, 132, 82-88.	3.1	48
86	Activational Effects of Gonadal Steroids on Hypothalamoâ€Pituitaryâ€Adrenal Regulation in the Rat Disclosed by Response to Dexamethasone Suppression. Journal of Neuroendocrinology, 1997, 9, 129-134.	2.6	30
87	Changes in Sleepâ€Endocrine Activity after Growth Hormoneâ€Releasing Hormone Depend on Time of Administration. Journal of Neuroendocrinology, 1997, 9, 201-205.	2.6	40
88	Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression, 1996, 4, 1-13.	0.6	84
89	Morphine-Induced Locomotor and Neurochemical Stimulation is Enhanced in Transgenic Mice with Impaired Glucocorticoid Receptor Function. Journal of Neuroendocrinology, 1996, 8, 93-97.	2.6	27
90	Long-Term Antidepressant Treatment Reduces Behavioural Deficits in Transgenic Mice with Impaired Glucocorticoid Receptor Function. Journal of Neuroendocrinology, 1995, 7, 841-845.	2.6	160

#	Article	IF	CITATIONS
91	The Neuroactive Steroid 5?-Tetrahydrodeoxycorticosterone Increases GABAergic Postsynaptic Inhibition in Rat Neocortical Neurons in vitro. Journal of Neuroendocrinology, 1995, 7, 233-240.	2.6	26
92	Interleukinâ€1β Stimulates both Central and Peripheral Release of Vasopressin and Oxytocin in the Rat. European Journal of Neuroscience, 1995, 7, 592-598.	2.6	120
93	Intraperitoneal Administration of Bacterial Endotoxin Enhances Noradrenergic Neurotransmission in the Rat Preoptic Area: Relationship with Body Temperature and Hypothalamic-Pituitary-Adrenocortical Axis Activity. European Journal of Neuroscience, 1995, 7, 2418-2430.	2.6	88
94	Soluble interleukinâ€6 (ILâ€6) receptor augments central effects of ILâ€6 in vivo. FASEB Journal, 1995, 9, 659-664.	0.5	159
95	Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cellular and Molecular Neurobiology, 1994, 14, 579-588.	3.3	77
96	Differential signal transduction by five splice variants of the PACAP receptor. Nature, 1993, 365, 170-175.	27.8	1,156
97	Cellular Localization of Interleukin 6 mRNA and Interleukin 6 Receptor mRNA in Rat Brain. European Journal of Neuroscience, 1993, 5, 1426-1435.	2.6	301
98	Nocturnal plasma levels of cytokines in healthy men. European Archives of Psychiatry and Clinical Neuroscience, 1992, 242, 53-56.	3.2	133
99	Antiglucocorticoid treatment disrupts endocrine cycle and nocturnal sleep pattern. European Archives of Psychiatry and Clinical Neuroscience, 1992, 241, 372-375.	3.2	30
100	Research Activity at the Max Planck Institute for Psychiatry (Munich): Depression in Later Life. International Psychogeriatrics, 1991, 3, 75-78.	1.0	0